Cargando…
Effector function of anti-pyroglutamate-3 Aβ antibodies affects cognitive benefit, glial activation and amyloid clearance in Alzheimer’s-like mice
BACKGROUND: Pyroglutamate-3 Aβ (pGlu-3 Aβ) is an N-terminally truncated and post-translationally modified Aβ species found in Alzheimer’s disease (AD) brain. Its increased peptide aggregation propensity and toxicity make it an attractive emerging treatment strategy for AD. We address the question of...
Autores principales: | Crehan, Helen, Liu, Bin, Kleinschmidt, Martin, Rahfeld, Jens-Ulrich, Le, Kevin X., Caldarone, Barbara J., Frost, Jeffrey L., Hettmann, Thore, Hutter-Paier, Birgit, O’Nuallain, Brian, Park, Mi-Ae, DiCarli, Marcelo F., Lues, Inge, Schilling, Stephan, Lemere, Cynthia A. |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
BioMed Central
2020
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6958628/ https://www.ncbi.nlm.nih.gov/pubmed/31931873 http://dx.doi.org/10.1186/s13195-019-0579-8 |
Ejemplares similares
-
Development of the clinical candidate PBD-C06, a humanized pGlu3-Aβ-specific antibody against Alzheimer’s disease with reduced complement activation
por: Hettmann, Thore, et al.
Publicado: (2020) -
Immunotherapy targeting pyroglutamate-3 Aβ: prospects and challenges
por: Cynis, Holger, et al.
Publicado: (2016) -
Combination of the Glutaminyl Cyclase Inhibitor PQ912 (Varoglutamstat) and the Murine Monoclonal Antibody PBD-C06 (m6) Shows Additive Effects on Brain Aβ Pathology in Transgenic Mice
por: Hoffmann, Torsten, et al.
Publicado: (2021) -
Passive Aβ Immunotherapy: Current Achievements and Future Perspectives
por: Schilling, Stephan, et al.
Publicado: (2018) -
Passive Immunization against Pyroglutamate-3 Amyloid-β Reduces Plaque Burden in Alzheimer-Like Transgenic Mice: A Pilot Study
por: Frost, Jeffrey L., et al.
Publicado: (2012)